ResearchMoz added Latest Research Report titled " Global Type 1 Diabetes Market 2016-2020 " to it's Large Report database.
About Type 1 Diabetes Drugs
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Introduction
Risk factors
Diagnosis
Management
Epidemiology
Economic burden
PART 06: Insulin: An overview
Product portfolio
Global human insulin market
PART 07: Pipeline analysis
Faster-acting insulin aspart (NN1218)
Farxiga/Forxiga
SAR342434
NN9211
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
About Type 1 Diabetes Drugs
Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Technavios analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Introduction
Risk factors
Diagnosis
Management
Epidemiology
Economic burden
PART 06: Insulin: An overview
Product portfolio
Global human insulin market
PART 07: Pipeline analysis
Faster-acting insulin aspart (NN1218)
Farxiga/Forxiga
SAR342434
NN9211
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment